eFFECTOR Therapeutics, Inc. (EFTR)
(Delayed Data from OTC)
$0.03 USD
-0.01 (-32.22%)
Updated Aug 29, 2024 02:51 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
eFFECTOR Therapeutics, Inc. [EFTR]
Reports for Purchase
Showing records 1 - 7 ( 7 total )
Company: eFFECTOR Therapeutics, Inc.
Industry: Unclassified
Company: eFFECTOR Therapeutics, Inc.
Industry: Unclassified
Market Overreaction to Failed Tomivosertib Trial Creates Buying Opportunity; Lowering PT to $12
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: eFFECTOR Therapeutics, Inc.
Industry: Unclassified
Two Datasets Imminent; 2023 Financials Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: eFFECTOR Therapeutics, Inc.
Industry: Unclassified
Looking Forward to Two Datasets This Year; Revising PT to $24
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: eFFECTOR Therapeutics, Inc.
Industry: Unclassified
Two Clinical Datasets Imminent; 3Q23 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: eFFECTOR Therapeutics, Inc.
Industry: Unclassified
Next-Gen Approaches to Targeted Cancer Therapy; Initiating at Buy and $5 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: eFFECTOR Therapeutics, Inc.
Industry: Unclassified
|